18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
This marks a meaningful step in the company's continued expansion in the region
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
Subscribe To Our Newsletter & Stay Updated
